Replimune Group, Inc. (REPL) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.66
↓-67% vs avg
5yr avg: 2.04
30Y Low1.5·High2.8
ROE
↓
-62.6%
↑-61% vs avg
5yr avg: -38.9%
30Y Low-63%·High-24%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
REPL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Replimune Group, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $272M | $785M | $544M | $1.0B | $887M | $1.4B | $342M | $353M | — | — |
| Enterprise Value | $237M | $751M | $545M | $942M | $813M | $1.3B | $324M | $334M | — | — |
| P/E Ratio → | -1.11 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.66 | 1.89 | 1.45 | 1.85 | 2.16 | 2.83 | 1.86 | 2.56 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
REPL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
REPL Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -62.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -62.6% | -62.6% | -46.4% | -36.1% | -25.9% | -23.7% | -32.7% | -56.2% | — | — |
| ROA | -47.6% | -47.6% | -38.0% | -31.5% | -23.5% | -20.8% | -27.1% | -28.1% | -44.8% | -33.8% |
| ROIC | -51.9% | -51.9% | -41.7% | -32.9% | -26.5% | -24.1% | -29.6% | -63.5% | — | — |
| ROCE | -55.9% | -55.9% | -44.3% | -33.6% | -25.1% | -22.0% | -30.7% | -30.3% | -47.6% | -46.3% |
REPL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $111M exceeds total debt of $76M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.20 | 0.11 | 0.08 | 0.07 | 0.23 | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | 0.00 | -0.15 | -0.18 | -0.30 | -0.10 | -0.14 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -33.15 | -33.15 | -35.25 | -42.57 | -54.65 | -27.05 | -29.29 | — | — | — |
Net cash position: cash ($111M) exceeds total debt ($76M)
REPL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Replimune Group, Inc.'s current ratio of 7.95x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 17.52x to 7.95x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.95 | 7.95 | 10.72 | 17.52 | 19.46 | 33.25 | 14.68 | 14.26 | 12.53 | 11.29 |
| Quick Ratio | 7.95 | 7.95 | 10.72 | 17.52 | 19.46 | 33.25 | 14.68 | 14.26 | 12.53 | 11.29 |
| Cash Ratio | 7.76 | 7.76 | 10.40 | 17.25 | 19.06 | 32.74 | 14.20 | 13.64 | 11.92 | 10.37 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
REPL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Replimune Group, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $81M | $67M | $58M | $52M | $46M | $34M | $23M | $31M | $31M |
Peer Comparison
Compare REPL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 REPLYou | $272M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 AMGN | $179B | 23.3 | 14.1 | 22.1 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 CGEN | $247M | -17.3 | — | 5.0 | 71.5% | -53.4% | -23.6% | -24.1% | — |
 IOVA | $2B | -3.8 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.5 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 ADCT | $491M | -3.4 | — | — | 90.6% | -133.2% | — | — | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 MRK | $280B | 15.6 | 10.8 | 22.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See REPL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs REPL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare REPL vs AMGN
Side-by-side business, growth, and profitability comparison vs Amgen Inc..
Start ComparisonREPL — Frequently Asked Questions
Quick answers to the most common questions about buying REPL stock.
What is Replimune Group, Inc.'s P/E ratio?
Replimune Group, Inc.'s current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.
What is Replimune Group, Inc.'s ROE?
Replimune Group, Inc.'s return on equity (ROE) is -62.6%. The historical average is -40.5%.
Is REPL stock overvalued?
Based on historical data, Replimune Group, Inc. is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.